SCHEDULE OF REPORTABLE SEGMENT LOSS (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2024 |
Mar. 31, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Total research and development | $ 2,167,114 | $ 1,713,973 | $ 4,977,954 | $ 3,305,115 | ||
| General and administrative | 2,289,649 | 2,394,912 | 4,051,368 | 4,747,009 | ||
| Other income, net | (15,547) | (93,618) | (55,676) | (230,180) | ||
| Change in fair value of convertible promissory notes | 787,703 | 787,703 | ||||
| Net loss | 5,228,919 | $ 4,532,430 | 4,015,267 | $ 3,806,677 | 9,761,349 | 7,821,944 |
| External Research And Development [Member] | ||||||
| Total research and development | 1,687,877 | 923,864 | 4,003,989 | 1,704,764 | ||
| Internal Personnel Costs [Member] | ||||||
| Total research and development | $ 479,237 | $ 790,109 | $ 973,965 | $ 1,600,351 | ||
| X | ||||||||||
- Definition Change in fair value of convertible promissory notes. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|